Skip to content

Australia has the highest prevalence of psoriasis in the APAC region

Australia has the highest prevalence of psoriasis in the APAC region 1

According to Arthritis Foundation, the prevalence of psoriatic arthritis in patients suffering from psoriasis is approximately between 7 and 48. Europe is the second largest market for psoriatic arthritis pharmacotherapy as it’s the region expected to observe rapid aging population. In Asia-Pacific China, India, Japan, South Korea and Australia are observed to be the leading geographies in psoriatic arthritis. Keywords: Asia-Pacific, Compliance, Plaque psoriasis, Reimbursement, Ustekinumab. The compliance rate in Korean patients was higher than in other Asia-Pacific patients at all postbaseline visits; compliance appeared to decline from week 28 onward in non-Korean patients. This was a phase 4, multicenter, open-label observational study designed to determine how patients use ustekinumab in a naturalistic setting in the Asia-Pacific region and to examine efficacy outcomes in Korean patients. This strategic plan has been developed to ensure Australia maintains its low levels of tuberculosis. Indigenous Australians have higher rates of infection, disease, hospitalisation and mortality from TB than non-Indigenous Australians. Therefore, those on high dose corticosteroid treatment or tumour necrosis factor (TNF) inhibitors, now used widely for the management of rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease and prospective transplant recipients, require appropriate screening and treatment for TB infection prior to commencing immunosuppression.

Australia has the highest prevalence of psoriasis in the APAC region 2Annual forecasts are provided for each region for the period 2006 through 2015. Arthritis I-3 Multiple Sclerosis I-4 Psoriasis I-4 Crohn’s disease I-4. II. Incidence and Prevalence Higher in Urban and Developed Regions II-15 Diagnosis II-16 Treatment of Rheumatoid Arthritis II-16 BRMs Revolutionize RA Treatment II-16 Drugs Used in Treating Rheumatoid Arthritis II-17. High prevalence of diseases such as psoriasis, multiple sclerosis, inflammatory bowel disease and autoimmune diseases is likely to play a key role in driving the market growth for anti-inflammatory peptides. In February 2013, Phylogica, a leading peptide drug discovery company, and Bio-Link Australia signed an agreement to commercialize anti-inflammatory Phylomer peptides for pharmaceutical use. Globally, North America, Europe, Asia-Pacific and Rest of the World (RoW) are the four major regions for which anti-inflammatory peptides market has been analyzed. The growing economy of countries such as India and China, and continuously improving healthcare scenario of Asia-Pacific region are the key factors driving the market growth in the region. Developed countries tend to have a higher burden of gout than developing countries, and seem to have increasing prevalence and incidence of the disease. Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002 2003. Systematic review of the prevalence of gout and hyperuricaemia in Australia. Merola, J. F., Wu, S., Han, J., Choi, H. K. & Qureshi, A. A. Psoriasis, psoriatic arthritis and risk of gout in US men and women.

Historically, treatment options for psoriatic arthritis have favoured non-steroidal anti-inflammatory drugs and disease modifying antirheumatic drugs. In most cases, a rheumatologist did the rheumatic assessments and diagnosed psoriatic arthritis; when this was not possible, joint evaluations were done by trained assessors. We analysed continuous and ordinal end points by using analysis of covariance stratified by geographical region and using baseline as covariate or analysis of variance if the baseline value was not available. Eating disorders have the highest mortality of any mental illness, according to the National Association of Anorexia Nervosa and Associated Disorders, due to the strain on the body, the frequent comorbidity with mood disorders, and a high suicide rate. Eating disorders have the highest mortality of any mental illness, according to the National Association of Anorexia Nervosa and Associated Disorders, due to the strain on the body, the frequent comorbidity with mood disorders, and a high suicide rate. Anne Fourie, PhD, is Disease Area Leader, Psoriasis, Janssen Research & Development, LLC. Approval provides new therapeutic option for plaque psoriasis patients aged 12 and older for whom limited approved treatment options are available. Asia Pacific (Regional). Adverse events occurred in 81.8 percent of the patients treated with STELARA through week 60, with 5.

Reportlinker Adds Autoimmune Disease Therapeutics

Epidemiological studies of rheumatic diseases have been conducted during the past 20 years in China. 93, with the highest rate being reported from a Taiwan urban area. ILAR and the Asia Pacific League of Associations for Rheumatology (APLAR) 3, and many other surveys were conducted either in cooperation with developed countries such as the USA 4 or by Chinese experts alone. Melbourne, Australia; s182. Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 – Advent of Novel Biologics and Expa. Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition. Most anal cancers are caused by the human papilloma virus (HPV) infection. The incidence is increasing, especially in high-risk individuals such as HIV-positive men. Registration and Reimbursement of New Cancer Medicines in Australia. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The University of Queensland, commonly referred to as UQ, is an Australian public research university primarily located in Queensland’s capital city, Brisbane. Founded in 1909, UQ is one of Australia’s oldest, most selective and comprehensive universities. UQ’s main campus at St Lucia has also been voted as one of the most beautiful in the world.

Comparison Of Two Etanercept Regimens For Treatment Of Psoriasis And Psoriatic Arthritis: Presta Randomised Double Blind Multicentre Trial